Printed from https://fiscalreceipts.com/program/0604807A/ — data as of July 28, 2026. Every figure is citation-backed; see the page online for per-number provenance.
Medical Materiel/Medical Biological Defense Equipment - Eng Dev
Budget Figures
FY2026 award data is a partial year — USASpending awards are reported on a rolling basis and the fiscal year does not close until September 30. why partial FY2026 data? →
- FY24
- $11.0M
- FY25
- $7.14M
- FY26
- $6.25M
● actuals (line) · ○ enacted · ◇ request — gaps are editions the program is absent from, never interpolated.
| Series | FY15 | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actuals | $29.4M | $39.3M | $36.2M | $36.7M | $45.1M | $70.5M | $48.3M | $43.0M | $25.0M | $11.0M | ||
| Enacted | $45.4M | $41.1M | $39.2M | $44.5M | $48.3M | $51.3M | $44.4M | $5.51M | $6.50M | $7.14M | ||
| Request | $41.1M | $39.2M | $44.5M | $48.3M | $49.9M | $44.4M | $5.51M | $6.50M | $7.14M | $6.25M |
blank = series not published for this year; – = absent from that edition.
Asked vs spent: the PB2020 book requested $48.3M for FY2020; the PB2022 book reports $70.5M actually spent — $22.2M above the request.
Program Lineage
No predecessor/successor lineage was recorded for this program element — no FY-to-FY transfer into or out of this line was stated in the ingested J-books, and none was inferred from the program structure.
Description
Mission — Medical Materiel/Medical Biological Defense Equipment - Eng Dev
This Program Element (PE) funds advanced development of medical materiel within the System Demonstration and Low Rate Initial Production portions of the acquisition life cycle using Budget Activity 6.5 (System Development and Demonstration) funding. It supports products successfully developed in the Systems Integration portion of the Systems Development and Demonstration phases through completion of the Milestone C Decision Review. Commercially-off-the-shelf (COTS) medical products are also tested and evaluated for military use, when available. This PE primarily includes pivotal (conclusive) human clinical trials necessary for licensure by the Food and Drug Administration (FDA). Projects in this PE include the following: Project 832 funds the engineering and manufacturing development of medical products for enhanced combat casualty care and follow-on care, including rehabilitation. Mature COTS medical products are also evaluated for military use. Consideration will also be given to reduce the medical sustainment footprint through smaller weight and cube volume, or equipment independence from supporting materiel. Products from this project will normally transition to OPA Funds. The FY 2026 request was reduced by $0.344 million for Advisory and Assistance Services to promote efficiencies and advance the policies of the Administration in alignment with Executive Order 14222, "Implementing the President's Department of Government Efficiency Cost Efficiency Initiative." The FY 2026 request was reduced by $0.049 million for civilian personnel to optimize the workforce in compliance with Executive Order 14210, "Implementing the President's Department of Government Efficiency Workforce Optimization Initiative."
Mission — Field Medical Systems Engineering Development
This Project funds the engineering and manufacturing development of medical products for enhanced combat casualty care and follow-on care. Commercially available medical products are also evaluated for military use. This project funds pivotal (conclusive) human clinical trials or mechanical engineering evaluations for effectiveness of devices or biologics (products derived from living organisms) to fulfill unique military requirements. Project Managers also consider reductions to the medical sustainment footprint through smaller weight and cube volume, or equipment independence from supporting materiel. This work is frequently completed through a laboratory/contractor team with the contractor obtaining the U.S. Food and Drug Administration (FDA) licensure for sale of the product.
Justification
Accomplishments & Planned Programs (1)
Field Medical Systems Engineering Development - Medical Readiness
Funding is provided for engineering and manufacturing development of medical products for diagnostic devices and testing of medical devices for use in the field.
Budget Line Items(workbook-cited)
Exhibit R-1
| Account | Org | Type | Amount |
|---|---|---|---|
| Research, Development, Test and Evaluation, Army | A | FY24 Actuals | $11.0M |
| Research, Development, Test and Evaluation, Army | A | FY25 Enacted | $7.14M |
| Research, Development, Test and Evaluation, Army | A | FY25 Total | $7.14M |
| Research, Development, Test and Evaluation, Army | A | FY26 Disc. Request | $6.25M |
| Research, Development, Test and Evaluation, Army | A | FY26 Total | $6.25M |
Budget Details(R-2/P-40 facts)
| Project | FY24 Actuals | FY25 Total | FY26 Base | FY26 Request |
|---|---|---|---|---|
| 832: Field Medical Systems Engineering Development | $11.0M | $7.14M | $6.25M | $6.25M |
| Program Element | $11.0M | $7.14M | $6.25M | $6.25M |
No follow-the-dollar view — this program's awards haven't been crosswalked at high confidence (flows cover 17 of 1741 programs). why coverage is partial? →
Awards
No awards are linked to this program element at high confidence — the budget→award crosswalk only asserts links it can defend, and this line has none yet.
Lobbying Mentions
No Senate LDA lobbying filing in the tracked data mentions this program element by code or alias.
No research dossier for this program — dossiers cover 50 of 1741 programs, the largest fully J-book-detailed lines by FY2026 requested dollars. why no dossier here? →